Dapivirine Vaginal Ring 25 mg is a silicone vaginal ring for HIV-1 prevention in women, designed to release dapivirine over one month. It is intended for women aged 16+ in combination with safer-sex practices when oral PrEP is not feasible. The product received a positive EMA opinion under the EU-M4all pathway for use outside the EU.
South Africa is working to identify local manufacturers for lenacapavir, a twice-yearly injectable HIV prevention drug that showed near-perfect efficacy in clinical trials. Kenya has already received 21,000 doses of the medication.
Zimbabwe began rolling out lenacapavir, a twice-yearly injectable HIV prevention drug, on February 19 in Epworth. The program will initially target more than 46,000 people at high risk across 24 sites nationwide.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02010593 |
Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women |
COMPLETED | PHASE2 |
| NCT01363037 |
Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring |
COMPLETED | PHASE1 |
